Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Enzymatica

2.93

 

SEK

 

-3.3 %

Less than 1K followers

ENZY

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Compare
-3.3%
-16.29%
+99.32%
+85.44%
+67.43%
+9.64%
-32.99%
-71.31%
-48.71%

Enzymatica is a life science company that develops and sells medical devices for infection-related diseases. The products are based on barrier technology, which includes marine enzymes. The company's first product is ColdZyme® Mouth Spray which can prevent colds as well as shorten the illness period. The product has been launched on several markets and the strategy is to expand to more markets via partners. The company is headquartered in Lund.

Read more
Market cap
711.21M SEK
Turnover
41.63K SEK
Revenue
45.58M
EBIT %
-114.22 %
P/E
-
Dividend yield-%
-
Financial calendar
17/7
2025

Interim report Q2'25

30/10
2025

Interim report Q3'25

18/2
2026

Annual report '25

All
Press releases
3rd party
ShowingAll content types
Press release5/14/2025, 1:10 PM

BioStock: Vetenskapen bakom ColdZyme – Insikter från professorer

Enzymatica
Press release5/14/2025, 1:10 PM

BioStock: The science behind ColdZyme – Insights from professors

Enzymatica
Regulatory press release5/7/2025, 1:44 PM

Kommuniké från årsstämma i Enzymatica AB (publ) den 7 maj 2025

Enzymatica

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/7/2025, 1:44 PM

Bulletin from the annual general meeting of Enzymatica AB (publ) on May 7, 2025

Enzymatica
Press release5/5/2025, 9:15 AM

Enzymatica AB: BioStock: Enzymatica rustar för global expansion efter starkt första kvartal

Enzymatica
Press release5/5/2025, 9:15 AM

Enzymatica AB: BioStock: Enzymatica gears up for global expansion after a strong first quarter

Enzymatica
Regulatory press release4/29/2025, 6:30 AM

Enzymatica AB: Quarterly report Q1/2025: Enzymatica strengthens its position in home markets and focuses on international expansion

Enzymatica
Regulatory press release4/29/2025, 6:30 AM

Enzymatica AB: Kvartalsrapport Q1/2025: Enzymatica stärker positionen på hemmamarknader och fokuserar på internationell expansion

Enzymatica
Regulatory press release4/10/2025, 6:30 AM

Enzymatica AB: Enzymatica publicerar årsredovisning för 2024

Enzymatica
Regulatory press release4/2/2025, 12:45 PM

Notice of Annual General Meeting 2025 in Enzymatica AB (publ)

Enzymatica
Regulatory press release4/2/2025, 12:45 PM

Kallelse till årsstämma 2025 i Enzymatica AB (publ)

Enzymatica
Press release3/11/2025, 7:15 AM

Enzymatica AB: BioStock: Enzymatica's results published in The Journal of Physiology

Enzymatica
Press release3/11/2025, 7:15 AM

Enzymatica AB: BioStock: Enzymaticas resultat publiceras i The Journal of Physiology

Enzymatica
Press release3/6/2025, 11:02 AM

Enzymatica AB: Replay Link to Digital Press Briefing - March 5, 2025

Enzymatica
Press release3/6/2025, 11:02 AM

Enzymatica AB: Länk till repris av digital pressträff 5 mars 2025

Enzymatica
Press release2/28/2025, 4:30 PM

Enzymatica AB: Inbjudan till presskonferens - 5 mars 2025

Enzymatica
Press release2/28/2025, 4:30 PM

Enzymatica AB: Invitation to Press Briefing - 5 March 2025

Enzymatica
Regulatory press release2/28/2025, 3:00 PM

Enzymatica AB: Nya oberoende studier visar att ColdZyme verkar på grundorsaken till luftvägsinfektioner och minskar antalet sjukdagar och symtom

Enzymatica
Regulatory press release2/28/2025, 3:00 PM

Enzymatica AB: New independent studies show that ColdZyme addresses the root cause of respiratory infections, reducing sick days and symptoms

Enzymatica
Press release2/25/2025, 8:27 AM

Enzymatica AB: BioStock: Ökad omsättning i Q4 men potential för bättre partnerförsäljning för Enzymatica

Enzymatica
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team